Embed Size (px)
Citation preview
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
U.S. Emerging Ovarian Cancer Therapeutics Markets
High Relapse Rate Drives Demand for Expanded Treatment Options
“The high relapse rate will continue to drive demand for a wider range of therapeutic options. With a myriad of new products currently in
development, this market is poised to expand rapidly.”
Pharmaceuticals Analyst Team
Frost & Sullivan
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
Frost & Sullivan provides:
• Detailed insights into recent developments and trends
• Drivers, restraints, challenges, and strategic recommendations
• Analyst insights on ‘hot topics’ and emerging applications in the Ovarian Cancer Therapeutics market
• Market sizing and competitive analysis
• Market forecasts and opportunity analysis
• Quarterly assessments
• End-user analysis
Key Features
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
• Coverage: The United States
• Proven methodology encompassing extensive primary and secondary data and research
• Focused information and strategies that cover business and technology issues
• Credible data and analyses highlighting industry dynamics
• Winning strategies to help you create precise business plans
What We Offer
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
Current Market Participants• Find out where you stand in comparison with competitors• Assess current and future drivers and restraints• Determine and exploit new market share opportunities
New Entrants • Analyze challenges associated with the industry• Calculate time scales for strategy implementation• Position yourself to capitalize on the market’s unmet needs
Investment Community• Analyze long-term strategies of companies• Determine which participants will outperform the competition• Assess attractiveness of investing in the market
Who Will Benefit?
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
AltaRex, Inc.ALZA Corp.Antisoma plcAstraZeneca PharmaceuticalsAVAX Technologies, Inc.Aventis Pharmaceuticals, Inc.Bristol-Myers Squibb, Inc.Celgene Corp.Cytran, Inc.Eli LillyGenaera Corp.Genentech, Inc.Gilead Sciences, Inc.GlaxoSmithKlineGuilford Pharmaceuticals, Inc.InterMune Pharmaceuticals, Inc.Intracel Corp.
Introgen Therapeutics, Inc.ISIS Pharmaceuticals, Inc.Johnson & JohnsonMedarex, Inc.MGI Pharma, Inc.Millennium Pharmaceuticals, Inc.NeoPharm, Inc.Novartis OncologyOnyx Pharmaceuticals, Inc.OSI Pharmaceuticals, Inc.Pharmacia Corp.Roche US PharmaceuticalsSchering-Plough Corp.Seattle Genetics, Inc.SuperGen, Inc.Targeted Genetics Corp.Telik, Inc.Vertex Pharmaceuticals, Inc.
Key Market Participants
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
• Call toll free 877 GO FROST
(877.463.7876)
• Fax toll free 888.690.3329
• E-mail [email protected]
• Visit www.frost.com
For More Information
![Relapse of drug addictors; A review€¦ · 2.Relapse rate: Relapse is very common after treatment for drug addiction [3], it was stated that 25-50% of substance abusers will relapse](https://img.pdfslide.us/doc/110x75/5f2c786cf88b454211793241/relapse-of-drug-addictors-a-review-2relapse-rate-relapse-is-very-common-after.jpg)
